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A cyclic adenosine monophosphate binding abnorm-
ality in psoriatic erythrocytes that could be corrected
by retinoid treatment has been reported. It was
tested whether this binding abnormality is speci®c
for psoriasis and the effects of treatment were com-
pared with etretinate, cyclosporine A, or anthralin
on 2-3H-8-N3-cyclic adenosine monophosphate
binding to the regulatory subunit of protein kinase A
in erythrocyte membranes. One hundred and ®fteen
individuals were evaluated, including: (i) 34 healthy
persons; (ii) 15 patients with nonatopic in¯ammatory
skin diseases (eczema, erythroderma, tinea, Grover's
disease, erysipelas, urticaria); (iii) eight with other
dermatoses mediated by immune mechanisms (sys-
temic lupus erythematosus, lichen planus, necrotiz-
ing vasculitis, erythema nodosum, systemic
sclerosis); (iv) 14 with generalized atopic dermatitis;
and (v) 44 with psoriasis vulgaris clinically assessed
by Psoriasis Area and Severity Index. In psoriasis,
the course of the binding of 2-3H-8-N3-cyclic adeno-
sine monophosphate to erythrocytes was measured
in nine patients during a 10 wk treatment with etreti-
nate, in 21 patients during a 10 wk treatment with
cyclosporine A, and one patient under topical treat-
ment with anthralin for 4 wk. We found the follow-
ing femtomolar binding per mg protein: (i) healthy
persons (1064 6 124, mean 6 SD); (ii) nonatopic
in¯ammatory skin diseases (995 6 103); (iii) immune
dermatoses (961 6 92); (iv) atopic dermatitis
(960 6 110); and (v) psoriasis (645 6 159; p < 0.0001
compared with nonpsoriatics, Mann±Whitney U
test). Treatment of psoriasis with etretinate, cyclo-
sporine A, or anthralin normalized the binding of
cyclic adenosine monophosphate, which was in-
versely correlated to the Psoriasis Area and Severity
Index score. It was concluded that the decreased
binding of cyclic adenosine monophosphate to
protein kinase A in erythrocytes is speci®c for psoria-
sis and normalizes after successful treatment. Key
words: anthralin/cyclosporine A/dermatitis/etretinate/
Psoriasis Area and Severity Index. J Invest Dermatol
119:160±165, 2002
I
n psoriasis, abnormalities of the cyclic adenosine monophos-
phate (cAMP) system of metabolic regulation have been
known for 30 y (Voorhees and Duell, 1971). In particular, a
signi®cant decrease in cAMP was found in involved psoriatic
epidermis when compared with uninvolved and control
epidermis (Voorhees et al, 1972a, b). In many cell types, cAMP
activates protein kinase A (PKA), which in turn phosphorylates
various substrate proteins. Because cAMP regulates glycogen
metabolism and promotes cell differentiation while limiting
proliferation, it was thought that the cAMP system might play a
part in the pathogenesis of psoriasis (Voorhees et al, 1972a, b). Later
on it was reported that cAMP was not decreased in psoriatic
epidermis compared with normal epidermis (Adachi et al, 1980).
Moreover, a decline in the response of cAMP to b-adrenergic
stimulation has been established (Yoshikawa et al, 1975; Eedy et al,
1990); however, no difference in PKA activity between psoriatic
epidermis and normal epidermis has been found (Nemoto et al,
1983). Clinically, it has been well known that b-adrenergic
antagonists as well as lithium salts or antimalarials, i.e., drugs that
reduce the intracellular accumulation of cAMP (Voorhees et al,
1975) are able to exacerbate psoriasis (summarized in Greaves and
Weinstein, 1995). Attempts to exploit therapeutically an altered
cAMP metabolism in psoriasis, however, have not proven fruitful.
Taken together, the pathophysiologic meaning of cAMP and PKA
in psoriasis remains unclear.
Two isoenzymes of PKA, PK1 and PK2, have been isolated.
PK1 and PK2 are inactive tetramers consisting of two identical
catalytic subunits and two regulatory subunits, RI and RII having
molecular weights of 47 and 54 kDa, respectively; in the absence of
cAMP binding to RI or RII, the substrate binding sites on the
catalytic subunits are blocked. Recent studies have indicated that
the levels of RI and RII are decreased in the cytosol of psoriatic
®broblasts and that RI in erythrocyte membranes from psoriatic
patients is lower than from normal subjects correlating with the
severity of the cutaneous manifestations (Brion et al, 1986). In
erythrocytes, PK1 is the only cAMP-dependent protein kinase
(Dreyfuss et al, 1978). A cAMP binding abnormality to the RI
regulatory subunit has been found in psoriatic erythrocytes; the
ability of RI to bind the cAMP analog 8-azido-32P-cAMP in
erythrocyte membranes has been found to be lower in psoriasis
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compared with control individuals, including 12 patients with
other forms of dermatitis (Raynaud et al, 1989). Furthermore, a
negative correlation between disease severity and the cAMP
analog-binding defect has been found that could be corrected
after long-term treatment with oral retinoid (Raynaud et al, 1989).
Oral administration of acitretin induced a rapid increase in the
ability of RI regulatory subunit of erythrocytes to bind cAMP
(Raynaud et al, 1993). In vitro exposure of erythrocytes from
psoriatic patients to retinoid also promoted an increase in binding
of cAMP to RI (Raynaud et al, 1993). In psoriatic ®broblasts, a
direct interaction of retinoic acid with RI and RII subunits of PKA
has been shown (Tournier et al, 1996). The effects of other forms of
treatment have not been examined; therefore, it was unclear
whether retinoid treatment was speci®c for correcting the cAMP
binding abnormality.
In order to test whether a diminished binding of cAMP to the
regulatory subunit RI of PKA in red blood cells is speci®c for
psoriasis, we measured the binding of the cAMP analog 2-3H-8-
N3-cAMP (azido-cAMP) to the RI subunit of PKA in erythrocyte
membranes in a large number of patients with psoriasis, compared
with healthy persons, and patients with atopic dermatitis and other
forms of dermatitis. Moreover, we compared the course of the
azido-cAMP binding the RI subunit of PKA in red blood cells
during systemic treatment of psoriasis with etretinate, the
immunosuppressant cyclosporine A, or topical treatment with
anthralin. This study's ®ndings indicate that a decreased binding of
azido-cAMP to erythrocyte membranes is speci®c for patients with
psoriatic skin lesions. Moreover, after successful treatment with
different modalities, the lower binding of cAMP to RI of PKA
normalizes.
MATERIALS AND METHODS
Subject The following subjects were studied: (i) 34 healthy
individuals; (ii) 15 patients with nonatopic in¯ammatory skin diseases,
including generalized eczema, nonpsoriatic erythroderma, tinea corporis,
Grover's disease, erysipelas (bacterial cellulitis), and urticaria; (iii) eight
with other dermatoses mediated by immune mechanisms termed
``immune dermatoses'' (including lupus erythematosus, generalized lichen
planus, necrotizing vasculitis, erythema nodosum, systemic sclerosis; (iv)
14 with generalized atopic dermatitis; and (v) 44 with psoriasis vulgaris.
None of the patients had received any systemic retinoids, corticosteroids,
or other immunosuppressants 4 wk before, or topical treatment other
than skin emollients 1 wk before examination. All individuals (115) were
in the age range of 18±75 y; the sex distribution was approximately
equal between males and females.
Nine patients with psoriasis were treated for 10 wk with a daily dose
of 50 mg etretinate, and 21 patients with 2.5±5.0 mg cyclosporine A per
kg body weight daily (Sandimmun, Novartis Pharma, Nuremberg,
Germany). These patients were enrolled in a treatment study, the details
of which have been published before (Schopf et al, 1992). The
Institutional Review Board approved this study. One psoriatic patient
was treated topically for 4 wk with anthralin±petrolatum compounds in
increasing anthralin concentrations starting with 1/16% anthralin; the
anthralin concentrations were doubled every 5±7 d up to 1%. The
severity of psoriasis was determined by the Psoriasis Area and Severity
Index (PASI) (Fredricksson and Petterson, 1978).
Isolation of erythrocyte membranes Erythrocyte membranes were
prepared according to the method described by Raynaud et al (1989). In
brief, 10 ml heparinized blood was collected and immediately spun at
1000 3 g for 30 min at 4°C. The erythrocyte pellet was suspended in
10 ml 0.172 mol per liter Tris±HCl (pH 7.6) and washed three times
with this buffer. The washed erythrocytes were then lyzed by suspension
in six volumes of hypotonic 0.011 mmol per liter Tris±HCl (pH 7.6)
and the membranes were isolated by centrifugation at 2000 3 g for
40 min. The membrane pellet was washed three times with 0.011 mol
per liter Tris±HCl (pH 7.6) and stored frozen at ±80°C until assay.
Chemicals used were purchased from Sigma (St Louis, MO) unless
otherwise stated.
In patients under treatment with etretinate and cyclosporine A, blood
was drawn at weeks 0, 1, 3, 6, and 10 of treatment. Blood from the
psoriatic patient under topical treatment with anthralin was drawn at
weeks 0, 1, 2, 3, and 4.
Synthesis of 2-3H-8-N3-cAMP (azido-cAMP) The method accord-
ing to Walter et al (1977) was employed. The reaction has the following
course:
2,8-3H-cAMP + Br2®2-3H-8-Br-cAMP + 3HBr
2-3H-8-Br-cAMP + (C2H5)3N-HN3®2-3H-8-N3-
cAMP + [(C2H5)3NH] Br
One millicurie of 2,8-3H-cAMP (speci®c activity 5 mCi per mmol,
New England Nuclear, Dreieich, Germany) was reacted with bromine in
1 ml acetate buffer (0.25 mol per liter, pH 3.9). The reaction was started
at 20°C by the addition of 12 mmol bromine (Merck, Darmstadt,
Germany). After 15 min the reaction mixture was concentrated to
0.3 ml by the addition of nitrogen gas. It was then separated by thin
layer chromatography on silica (GF 254 Merck) in the system 1-butanol/
acetic acid/H2O (ratio: 5:2:3 vol/vol/vol) employing a nonradioactive 8-
Br-cAMP standard (Sigma). Tritiated 8-Br-cAMP was eluted with
ethanol/H2O (Fluka, Buchs, Switzerland) 1:1 vol/vol and was dried by
nitrogen gas in a water bath. The residue was solubilized by diethyl
ammonium azide (5 mmol, Merck) in 3 ml dimethyl formamide (Merck)
and heated for 10 h at 75°C. The gemisch was concentrated to 1 ml at
37°C in a vacuum rotation vaporizer under the introduction of nitrogen
gas. This gemisch was loaded to a column of DEAE-cellulose in HCO3
form and was eluted with 30 ml triethylammonium bicarbonate in a
linear gradient of 0±0.2 mol per liter. A peak of radioactivity only
resulted for azido-cAMP. The radioactive-labeled elution fractions next
were pooled and vaporized in a vacuum in order to dry, and dissolved in
0.5 ml ethanol and stored in the dark at 4°C. The formula of azido-
cAMP is shown here:
Binding of azido-cAMP to the subunit RI of PKA of erythrocyte
membranes (Walter et al, 1977) The reaction mixture of 1 ml
consisted of 2-N-morpholino-ethanol-sulfonate (10 mmol per liter,
pH 6.2), magnesium chloride (10 mmol per liter), and cell membrane
protein (1 mg). The total binding of azido-cAMP was shown by the
three concentrations of 0.1, 0.5, and 2.0 mmol per liter. Duplicate
samples were used. The speci®c binding was determined after saturation
of nonspeci®c binding sites by the addition of cold N3-cAMP (2 mol per
liter). The reaction solutions were next incubated for 1 h at 4°C in the
dark. Next it was photoaf®nity labeled at room temperature of 20°C for
20 min under ultraviolet light at 254 nm. The reaction was stopped by
the addition of 0.2 ml sodium dodecyl sulfate (2.5%) and
mercaptoethanol (5%). Finally, the gemisch was heated for 5 min at
100°C.
The actual experimental cpm [3H]8-azido cAMP used were in the
order of 15,000 cpm; the radioactivity measuring binding with psoriatic
and normal erythrocyte membranes after electrophoresis was 850±
4000 cpm; background did not exceed 250 cpm.
Protein determination Protein concentration was determined
spectrophotometrically employing the Bio-Rad Protein microassay
(Bio-Rad, Munich, Germany) according to the manufacturer's
instructions.
Isolation and measurement of RI bound azido-cAMP Next, the
bound azido-cAMP was isolated and measured employing the Phast-
System (Pharmacia LKB-Phast Transfer, Freiburg, Germany; Phast
System Separation and Control Unit, Protein Blotting 220) on Phast Gel
(8±25) and sodium dodecyl sulfate buffer strips. Proteins with the relative
molecular mass of 47 kDa and 54 kDa (corresponding to the relative
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molecular masses of subunits RI and RII of PKA) were used. The azido-
cAMP binding subunit migrates in the 47 kDa fraction.
Five microliters of the above samples were pipetted to the gels and the
electrophoresis was started at a temperature of 15°C. After 30 min,
electrophoresis was terminated and protein blotting for 40 min employ-
ing the Phast-System on 20 mm thick nitrocellulose membranes was
done. The resulting bands on the nitrocellulose were stained with Phast-
Green FCF 1804301 (Pharmacia) using 40 parts methanol/10 parts acetic
acid/50 parts distilled water as well as 0.1% Phast-Green. Destaining of
unspeci®c staining was done with 25 parts methanol/10 parts acetic acid/
65 parts distilled water and 0.2 M NaOH. Next, the bands migrating
between the stained 47 kDa and 54 kDa on the nitrocellulose membrane
were cut out and transferred into 5 ml scintillation ¯uid. Radioactivity of
azido-cAMP was measured in a g-counter (Beckman b-counter LS
6800).
Calculation of the bound azido-cAMP was performed by Scatchard
plot employing the 2 3 3 samples. The ratio of the speci®cally bound
and free (unbound) azido-cAMP on the vertical axis was plotted against
the speci®cally bound azido-cAMP (fmol per mg protein) on the
horizontal axis. The intersection of the resulting straight line with the
horizontal axis indicates the maximal binding of azido-cAMP to the RI
subunit of PKA in the erythrocyte membranes.
Statistical evaluation The ®ndings were statistically compared by the
Mann±Whitney U test employing the statistical program MultiStat 1.13
for Macintosh computers, Biosoft (Cambridge, U.K.).
RESULTS
Binding of azido-cAMP to regulatory subunit RI of PKA in
erythrocyte membranes We compared the binding of azido-
cAMP in erythrocytes of 34 healthy individuals, 15 patients with
nonatopic forms of dermatitis, eight ``immune dermatoses'', and 14
atopic dermatitis, with 44 patients with psoriatic lesions. A
representative Scatchard plot analysis or the cAMP binding to red
blood cells is shown in Fig 1. The values of the dissociation
constant KD were in the order of 5.4 3 10
±8 [mol per liter] and
remained constant in the many samples examined (data not shown).
Figure 2 summarizes the results of the speci®c binding
comparing patients with controls. Compared with all the control
groups, we found a highly diminished binding of azido-cAMP to
the regulatory subunit RI of protein kinase in psoriatic erythrocytes
(p < 0.0001). We concluded that a decreased binding of azido-
cAMP to erythrocytes is speci®c for patients with psoriatic skin
lesions.
Effects of retinoid treatment on the binding of azido-
cAMP When the severity of psoriasis expressed as PASI was
plotted against the binding of azido-cAMP to erythrocyte
membranes, we found an inverse relationship between the two
parameters as depicted in Fig 3(i,e) when psoriasis was more
severe, there was less binding of azido-cAMP and vice versa.
Plotting both the PASI score and the binding of azido-cAMP
over the time of treatment, X-like curves resulted as depicted in
Fig 4.
From these results it was concluded that etretinate treatment of
psoriasis normalized the decreased binding of cAMP to erythro-
cytes.
Effects of cyclosporine A treatment on the binding of azido-
cAMP Similarly, when the binding of azido-cAMP was plotted
against the PASI, there was an analogous inverse relationship as
shown in Fig 5. Moreover, an X-like graph resulted, plotting both
PASI score and binding of azido-cAMP over the week of treatment
(Fig 6).
From these ®ndings it was concluded that treatment with
cyclosporine A also normalized the decreased binding of azido-
cAMP to the RI regulatory subunit of PKA.
Effects of topical treatment of psoriasis on the binding of
azido-cAMP in erythrocytes In the psoriatic patient topically
treated with anthralin, we also found that the decreased binding of
azido-cAMP to erythrocytes before treatment tended towards
normal during the course of treatment as shown in Fig 7.
From these ®ndings we concluded that both systemic treatment
with two different agents as well as topical treatment with anthralin
Figure 1. Scatchard plot analysis of the speci®c binding of azido-
cAMP to the regulatory subunit RI of PKA erythrocyte
membranes. Dissociation constant KD = (1040 3 10
±15 [mol per liter]/
0.19 3 10±4) = 5.4 3 10±8 [mol per liter]. KD values did not change
with different speci®c binding of azido-cAMP to erythrocyte membranes
during the course of treatment (data not shown).
Figure 2. Speci®c binding of azido-cAMP to the regulatory
subunit RI of PKA in erythrocyte membranes. Horizontal bars
denote the means. The p-value compares the psoriatic patients with the
different groups of control individuals each employing the Mann±
Whitney U test.
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normalize the diminished binding of azido-cAMP in erythrocyte
membranes.
DISCUSSION
This study clearly indicates that the 44 patients with psoriasis have a
markedly lower binding of azido-cAMP to the RI of PKA
compared with the 71 controls, including 34 healthy individuals
and 37 patients with other forms of dermatitis (including atopic
dermatitis), immune dermatoses (such as discoid lupus erythema-
tosus, necrotizing allergic vasculitis, erythema nodosum, systemic
sclerosis), and nonatopic in¯ammatory skin diseases (including
generalized eczema, stasis eczema, nummular eczema, deep
dermatophytosis, bacterial cellulitis, and urticaria). Although there
were slight variations in the level of cAMP binding in the different
forms of dermatitis and healthy controls, the psoriasis group clearly
exhibited the lowest binding, i.e., approximately 1000 vs 660 fmol
protein per mg, respectively, reaching the statistical signi®cance
level of p < 0.0001.
Moreover, we found a highly signi®cant inverse relationship
between disease severity and binding of azido-cAMP to the
regulatory subunit RI of PKA in psoriasis. This ®nding offers the
opportunity to determine the extent of psoriasis merely from a
blood sample. These ®ndings are consistent with previous results by
Raynaud et al (1989) who had studied a smaller number of patients
that had been treated with etretinate only. Our ®ndings in patients
who were treated systemically with cyclosporine A or topically
with anthralin indicate that the normalization of cAMP binding in
erythrocytes of psoriatic patients is not con®ned to retinoid
treatment but rather represents a general phenomenon in these
patients.
Interestingly, treatment of psoriatic patients with peptide T, an
octapeptide sequence found in human immunode®ciency virus
envelope glycoprotein pg120, has been observed to result in an
improvement in the psoriatic condition; exposure of psoriatic
®broblasts to peptide T resulted in an increased binding of cAMP to
the RI and RII regulatory subunits of PKA (Liapi et al, 1998).
Erythrocytes have not been examined in this respect. Furthermore,
the anti-in¯ammatory agent adenosine acting at its A(2A) receptor
and the selective A(2A) receptor agonist CGS-21680 (known to
suppress proin¯ammatory interleukin-12 and to increase anti-
in¯ammatory interleukin-10 on the monocytic cell line THP-1),
Figure 4. PASI compared with the binding of azido-cAMP to the
regulatory subunit RI of PKA in erythrocytes during the course
of a 10 wk treatment with etretinate.
Figure 5. Binding of azido-cAMP to the regulatory subunit RI of
PKA in erythrocyte membranes of psoriatic patients during the
course of a 10 wk treatment with cyclosporine A (CyA).
Figure 6. PASI compared with the binding of azido-cAMP to the
regulatory subunit RI of PKA in erythrocytes during the course
of a 10 wk treatment with cyclosporine A (CyA).
Figure 3. Binding of azido-cAMP to the regulatory subunit RI of
PKA in erythrocyte membranes of psoriatic patients during the
course of a 10 wk treatment with etretinate.
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have been found to stimulate an increase in intracellular cAMP in
interleukin-1 and tumor necrosis factor-a-treated cells (Khoa et al,
2001). As there is increased tumor necrosis factor-a expression in
psoriatic skin lesions (Nickoloff et al, 1991) and as the chimeric
monoclonal antibody against tumor necrosis factor-a, in¯iximab,
has been described to clear psoriatic skin lesions (Chaudhari et al,
2001; Schopf et al, in press), it seems likely that the therapeutic
effect of this agent also occurs together with an increased binding of
cAMP to RI of PKA.
Compared with radioactively labeling the phosphate residue on
azido-cAMP with 32P, which could more easily be cleaved, our
method of preparing tritiated azido-cAMP had the advantage of
tagging the core of the nucleotide resulting in a very stable label.
The fact that the KD values of azido-cAMP binding remained
unaltered after successful treatment or comparing psoriatic patients
with controls indicates that no structural or functional changes of
the regulatory unit RI of PKA had occurred in the erythrocyte
membranes. Tournier et al (1995) who studied modulation of the
cAMP-dependent regulatory subunit RI and RII of PKA in
®broblasts from patients with psoriasis reported that the decrease in
the binding of azido-cAMP occurred with no change in the level of
RII protein suggesting an altered post-transcriptional modi®cation
of the cAMP PKII in psoriatic ®broblasts, which could be reversed
by exposure of the cells to retinoic acid. Western blot analysis of RI
will further support the ®nding that decreased binding of cAMP to
RI represents a quantitative decrease in RI and is not due to
alterations in the cAMP binding af®nity of RI. We used
erythrocyte membranes for the cAMP binding measurement. It
would be interesting to examine whether RI/cAMP binding in the
cytosol of psoriatic red cells is also decreased. The amount of RI/
cAMP binding in the cytosol of ®broblasts, however, was reported
to be normal in ®ve of seven psoriatic patients and decreased in two
patients; in contrast, membrane-associated levels of RI were found
decreased in ®ve patients and normal in two psoriatic patients
(Raynaud et al, 1987). This may indicate that is less likely also to
®nd decreased RI/cAMP binding in the cytosol of red blood cells.
Several membrane alterations have been reported in psoriasis.
Morsches et al (1981) reported that patients with psoriasis exhibit a
decreased permeability of erythrocyte membranes for dehydro-
epiandrosterone. Partsch et al (1979) found an increased purine
salvage pathway in psoriatic erythrocytes. Semplicini et al (1988)
reported altered red blood cell membrane permeability for sodium
in psoriasis. Moreover, an altered erythrocyte membrane phos-
phorylation has been reported in psoriasis (Kumar et al, 1983);
compared with controls, membranes from psoriatic patients showed
less 32P incorporation into cell membranes. This latter abnormality
could well be related to the diminished binding of cAMP to the
erythrocyte membranes. Moreover, a decreased ceramide gener-
ation in psoriatic cell membranes has been found (Alessandrini et al,
2001). This may indicate that the membrane abnormality in
erythrocytes is part of a generalized phenomenon. These defects,
however, are not permanent but normalize during the clearing of
skin lesions, indicating that there is a functional defect and no
inherent structural cell membrane abnormality in psoriasis. It
should be emphasized here that the change in cAMP binding to RI
in psoriatic cells appears to be reversible and may not be caused by a
change in cell signaling, such as an increase in the oxidative state of
the cell in response to events, such as stress or trauma. As such, the
inability to bind cAMP will not be signi®cantly in¯uenced by
possible changes in the intracellular level of cAMP. This may
explain why attempts to in¯uence intracellular cAMP levels to treat
psoriasis would not be highly effective.
An important factor to explain the diminished binding of cAMP
to erythrocyte membranes could be increased oxidative stress in
psoriasis. Oxidative damage has been found in the dermis of
psoriatic skin lesions as measured by carbonylation of macro-
molecules, an indicator of oxidative stress (Dimon-Gadal et al,
2000). Anti-oxidant superoxide dismutase in psoriatic ®broblasts
and erythrocytes is signi®cantly higher in psoriatic patients than in
normal subjects (TheÂrond et al, 1996). Raynaud et al (1997) have
reported that free oxygen radicals lead to decreased binding of
cAMP in ®broblasts and that oxygen radical scavengers restored the
binding of cAMP to normal levels. Moreover, Tournier et al,
(1995) discovered that oxidative modi®cation of PKA decreased
the binding of cAMP while leaving the level of protein unaltered.
Previous studies have also reported on the effects of oxidative stress
in psoriasis; i.e., mononuclear leukocyte glucose-6-phosphate
dehydrogenase, which provides energy to generate oxygen radicals
in phagocytes, is enhanced in psoriasis (Schopf et al, 1986) and
psoriatic phagocytes exhibit an enhanced respiratory burst (Schopf
and Straussfeld, 1985). It could well be that the increased oxygen
radical generation in psoriasis is related to the diminished cAMP
binding to RI of PKA in psoriatic erythrocytes. From clinical
experience, however, it is doubtful whether counteracting
oxidative stress by oxygen radical scavengers or anti-oxidants will
suf®ce to clear psoriatic lesions. Studies have not yet been published
that clearly demonstrate that counteracting oxidative stress by
oxygen radical scavengers or anti-oxidants will not have a bene®cial
effect in the treatment of psoriasis.
The ®ndings of decreased binding of cAMP to PKA raise the
question of whether this is merely a speci®c, temporary bio-
chemical marker of psoriasis or whether this has pathogenic
relevance. It is possible that abnormalities of the cAMP system are
indeed intrinsically related to pathogenesis as ®rst suggested by
Voorhees and Duell, 1971; Voorhees et al., 1972a,b. The
provocation of psoriasis by agents known to inhibit the intracellular
accumulation of cAMP such as b-adrenergic antagonists, lithium,
or anti-malarials, also points in that direction (Voorhees et al, 1975;
summarized by Greaves and Weinstein, 1995). In addition, the
induction of major histocompatibility complex class II antigens by
b-adrenergic antagonists may play a part (Czernielewski et al, 1986)
in considering the concept that psoriasis is a T lymphocyte
mediated condition (Gottlieb et al, 1995). Moreover, it may well be
that the exacerbation of psoriasis observed in patients with alcohol
abuse may be related to the ®nding that ethanol caused a 43%
decrease in the amount of type I regulatory subunit of PKA
(Dohrman et al, 1996).
To summarize, our ®ndings indicate that in psoriasis there is a
highly decreased binding of cAMP to erythrocytes not present in
other forms of generalized dermatitis or in healthy controls.
Different forms of effective treatment normalize this defect. It
remains to be shown whether the decreased binding of cAMP to
red blood cells in psoriasis is a biochemical marker alone or whether
this defect does have pathogenic relevance.
Figure 7. Binding of azido-cAMP to the regulatory subunit RI of
PKA in erythrocyte membranes during the course of a 4 wk
topical treatment of a patient with anthralin-petrolatum.
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